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Abstract
Do mutations required for adaptation occur de novo, or are they segregating within popula-
tions as standing genetic variation? This question is key to understanding adaptive change
in nature, and has important practical consequences for the evolution of drug resistance.
We provide evidence that alleles conferring resistance to oxamniquine (OXA), an antischis-
tosomal drug, are widespread in natural parasite populations under minimal drug pressure
and predate OXA deployment. OXA has been used since the 1970s to treat Schistosoma
mansoni infections in the New World where S. mansoni established during the slave trade.
Recessive loss-of-function mutations within a parasite sulfotransferase (SmSULT-OR)
underlie resistance, and several verified resistance mutations, including a deletion (p.
E142del), have been identified in the New World. Here we investigate sequence variation in
SmSULT-OR in S. mansoni from the Old World, where OXA has seen minimal usage. We
sequenced exomes of 204 S. mansoni parasites from West Africa, East Africa and the Mid-
dle East, and scored variants in SmSULT-OR and flanking regions. We identified 39 non-
synonymous SNPs, 4 deletions, 1 duplication and 1 premature stop codon in the SmSULT-
OR coding sequence, including one confirmed resistance deletion (p.E142del). We
expressed recombinant proteins and used an in vitro OXA activation assay to functionally
validate the OXA-resistance phenotype for four predicted OXA-resistance mutations. Three
aspects of the data are of particular interest: (i) segregating OXA-resistance alleles are
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widespread in Old World populations (4.29–14.91% frequency), despite minimal OXA
usage, (ii) two OXA-resistance mutations (p.W120R, p.N171IfsX28) are particularly com-
mon (>5%) in East African and Middle-Eastern populations, (iii) the p.E142del allele has
identical flanking SNPs in both West Africa and Puerto Rico, suggesting that parasites bear-
ing this allele colonized the New World during the slave trade and therefore predate OXA
deployment. We conclude that standing variation for OXA resistance is widespread in S.
mansoni.
Author summary
It has been argued that drug resistance is unlikely to spread rapidly in helminth parasites
infecting humans. This is based, at least in part, on the premise that resistance mutations
are rare or absent within populations prior to treatment, and take a long time to reach
appreciable frequencies because helminth parasite generation time is long. This argument
is critically dependent on the starting frequency of resistance alleles–if high levels of
“standing variation” for resistance are present prior to deployment of treatment, resis-
tance may spread rapidly. We examined frequencies of oxamniquine resistance alleles
present in Schistosoma mansoni from Africa and the Middle East where oxamniquine has
seen minimal use. We found that oxamniquine resistance alleles are widespread in the
Old World, ranging from 4.29% in the Middle East to 14.91% in East African parasite
populations. Furthermore, we show that resistance alleles from West African and the
Caribbean schistosomes share a common origin, suggesting that these alleles travelled to
the New World with S. mansoni during the transatlantic slave trade. Together, these
results demonstrate extensive standing variation for oxamniquine resistance. Our results
have important implications for both drug treatment policies and drug development
efforts, and demonstrate the power of molecular surveillance approaches for guiding hel-
minth control.
Introduction
The rate at which drug resistance alleles (or any other beneficial alleles) spread within popula-
tions in response to a drug treatment (or any other selection pressure) is critically dependent
on the starting frequency of resistance alleles in the population when new drugs are deployed
[1,2]. If no such alleles are present when a novel drug is introduced, then there is a waiting
time for resistance alleles to arise. Furthermore, because the starting allele frequency will be 1/
(2Ne), where Ne is the effective population size, the vast majority of resistance alleles that arise
will be lost due to genetic drift and fail to establish [2,3] (Fig 1). The barrier to establishment is
particularly severe for recessive traits because these will be present in heterozygotes at low fre-
quency and therefore not exposed to selection. This effect, otherwise known as “Haldane’s
sieve” [4], may be particularly relevant for drug resistance evolution in diploid pathogens,
because resistance mutations in drug targets typically result in phenotypic resistance only
when two copies are present. However, if resistance alleles are already segregating as standing
variation in pathogen populations when drug treatment is initiated, then there is no waiting
time for mutations to arise. Furthermore, there is a high probability of fixation and spread is
rapid because many resistance alleles are present in homozygous recessive genotypes and
therefore exposed to selection. Hence, whether resistance alleles (or alleles for other traits)
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arise de novo or are segregating as standing variation, is a central question in evolutionary biol-
ogy and public health, and key to predicting the effective “shelf life” of new drug treatments
[3,5].
There is growing evidence for resistance to anti-helminthics in several helminths infecting
humans, including Onchocerca volvulus [6], the filarial nematode causing river blindness, and
in soil transmitted helminths (hookworm, whipworm and Ascaris roundworms) [7] which
cumulatively infect over one billion people worldwide [8]. However, perhaps the best under-
stood is oxamniquine resistance in schistosome blood flukes, for which the mechanism of
drug action and the genetic and molecular basis for drug resistance are now known. Oxamni-
quine (OXA) kills Schistosoma mansoni, but is ineffective against two other major schistosome
species infecting humans (S. haematobium and S. japonicum) [9]. OXA is a pro-drug that is
activated by a schistosome sulfotransferase (SmSULT-OR) encoded on chromosome 6 [10].
Loss-of-function mutations within SmSULT-OR result in resistance: only parasites that are
homozygous for resistance alleles are phenotypically resistant (OXA-R). We initially identified
the locus and mutation, a single amino acid deletion (p.E142del), underlying OXA-R using a
genetic cross involving a resistant parasite line selected from a parasite isolate from a Puerto
Rican patient in 1971 [11]. Additionally we identified a second mutation (p.C35R) in S. man-
soni obtained from an incurable Brazilian patient [12]. These two mutations result in disrup-
tion of the active site of the SmSULT-OR and inability to activate OXA [10]. Both p.E142del
and p.C35R, and two additional mutations resulting in truncated proteins, were subsequently
identified in a field survey of SmSULT-OR genetic variation of parasites from a single Brazilian
village [13]. The combined allele frequency of these four resistance alleles was 1.85%.
OXA was widely used in the New World, where only S. mansoni is present, during the
1970s to early 2000’s [14], so the OXA-R alleles we observed in Brazil [13] could conceivably
have resulted from drug selection. In contrast, OXA saw minimal usage in Africa where both
Fig 1. Drug resistance evolution from standing variation or de novo mutation. Drug resistance alleles spread
rapidly and reach fixation with a high probability when drug resistance alleles are already present as standing variation.
In contrast, if resistance alleles are absent when treatment is initiated, resistance mutation must arise de novo, so there
is a waiting time before the resistance alleles appear, and most resistance alleles are lost by genetic drift, so the
probability of establishment and fixation is low.
https://doi.org/10.1371/journal.ppat.1007881.g001
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S. haematobium and S. mansoni are present. In South America, an estimated 6 million doses of
OXA were used to treat the 7 million people infected with S. mansoni prior to 1987 [15]. In
contrast, 3 million doses had been used in Africa (Egypt, Ethiopia, Ivory Coast, Kenya, Mala-
gasy, Malawi, Rwanda-Burundi, South Africa, Sudan, Tanzania, Uganda, Zambia, Zaire) and
the Middle East (Arabian penensula) [15], where an estimated ~60 million people were
infected with S. mansoni [16]. Hence, OXA selection was minimal in Africa compared with
South America. The central aim of this paper is to determine whether de novo mutation or
standing variation best explains OXA-R in S. mansoni populations. To do this we examined
SmSULT-OR genetic variation in Old World parasite populations where OXA treatment has
been minimal.
Results
Samples
We sequenced exomes from 92 miracidia from Tanzania (n = 57), Niger (n = 10), and Senegal
(n = 25) from the SCAN collection at the Natural History Museum [17], with each miracidium
derived from a different patient. In addition, we included 112 samples collected from Oman:
these included 86 single worms and 26 pools of cercariae from single infected snails. The
Omani samples were derived from 11 human infections, 2 naturally infected rodents, and 26
naturally infected snails (Table 1). We obtained an average of 15.7 ± 8 (mean ± standard devia-
tion, s.d.) million reads per library (S1 Table). A very high proportion of these reads were
mapped to the reference genome (91.9 ± 6.29 (s.d.) % on average). We captured on average
99.08 ± 3.92 (s.d.) % of the bait regions. We obtained an average read depth of 64.40 ± 32.27 (s.
d.) in the bait regions. For SmSULT-OR, we obtained sequence across 95.06 ± 6.54 (s.d.) % of
the coding sequence with an average read depth of 43.09 ± 26.96 (s.d.).
We compared these Old World parasite samples with: (i) the OXA-R parasite from Puerto
Rico (HR) carrying the causative p.E142del mutation identified previously [10], for which
whole genome sequence is available, and (ii) published SmSULT-OR sequences from a single
Brazilian location (n = 189) [13] (Table 1).
New and known mutations identified in the SmSULT-OR gene
We identified a total of 85 SmSULT-OR mutations across all three populations (West Africa,
East Africa and Middle East), including 76 coding mutations and 9 non-coding mutations (S2
Table 1. Summary of the samples.
Location Sample
size
Parasite stage sampled Host Sequence Notesb
South America
(Brazil)a
189 Miracidia Human Sanger sequence of
SmSULT-OR exons
1–11 miracidia from each of 49 people from single village
[13]
West Africa (Niger/
Senegal)
25/10 Miracidia Human Exome sequence 1 miracidia from each person
East Africa
(Tanzania)
57 Miracidia Human Exome sequence 1 miracidia from each person
Middle East (Oman) 112 Miracidia/adult
worms/cercariae
Human/Rat/
Snail
Exome sequence 1–53 parasite genotypes analyzed per host from 11 people,
2 rats and 26 snails from 8 locations
Caribbean (Puerto
Rico)a
1 Adult worms Hamster Genome sequence OXA-resistant parasite used in a genetic cross [10]
a Data from Brazil from a previous study [13] added for comparison
b see S3 Table for detailed information on sample locations
https://doi.org/10.1371/journal.ppat.1007881.t001
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Table). Exon 1 carried 24 mutations. These included 13 non-synonymous single nucleotide
polymorphisms (SNPs), 8 synonymous SNPs, one duplication, one deletion, and one prema-
ture stop codon. Exon 2 carried 52 mutations: 26 non-synonymous SNPs, 23 synonymous and
three deletions. There were no differences in the density of mutations in the two exons (Fish-
er’s exact test, d.f. = 1, p = 0.09). The overall transition/transversion ratio was 1.94. Forty-three
percent (37/85 mutations) showed an average allele frequency greater than 5%.
Among the 85 mutations, we have previously found three coding and one non-coding
mutations in the New World (Caribbean and Brazil): the substitution p.P67L (g.200C>T), the
deletion p.E142del (g.4348_4350delGAA), the substitution p.L256W (g.4691T>G) and the 3’
untranslated region (UTR) substitution g.4720C>T [10,13]. Just one of these mutations (p.
E142del) encodes a confirmed OXA-R allele. Frequencies of all mutations in each population
are shown in S2 Table.
We measured nucleotide diversity (π) in both New and Old World populations. Nucleotide
diversity was the highest in Oman (π = 247.5 ± 3.4 × 10−4) followed by East Africa (π =
22.8 ± 2.3 × 10−4), West Africa (π = 7.2 ± 1.5 × 10−4) and Brazil (π = 2.1 ± 0.3 × 10−4). If drug
pressure drives the changes at SmSULT-OR, we might expect to see signals of positive selec-
tion. We examined sequence conservation by measuring proportions of non-synonymous dif-
ference per non-synonymous site relative to synonymous changes per synonymous site (Ka/
Ks) between S. mansoni and a S. rodhaini outgroup. Ka/Ks ranged from 0.20–0.24 suggesting
that changes at non-synonymous sites are 4–5 times less abundant than at synonymous sites,
consistent with weak purifying selection. Similarly, the ratio of non-synonymous polymor-
phisms per non-synonymous site relative to synonymous polymorphisms per synonymous
site (pN/pS) ranged from 0.11 to 1.23 and none of these values were significantly greater than
unity (Table 2). These tests did not provide evidence that SmSULT-OR is under positive
selection.
In vitro tests and in silico evaluation of impact of mutations
We used three approaches to identify SmSULT-OR mutations that are likely to result in
OXA-R.
Visual assessment. Some mutations have obvious deleterious effects on the protein by
introducing premature stop codons. This is the case for three mutations identified in
Table 2. Summary statistics for coding sequence variation in SmSULT-OR.
Location Nucleotide diversity
(π ± standard deviation)
Dn Pn Ds Ps N S pN/pS Ka/Ks
South America (Brazil)a 2.1 ± 0.3 × 10−4 17 4 23 0 598.19 163.81 N/C 0.202
West Africa (Senegal / Niger) 7.2 ± 1.5 × 10−4 19 9 23 2 600.93 164.07 1.229 0.225
East Africa (Tanzania) 22.8 ± 2.3 × 10−4 18 19 23 9 593.80 162.20 0.577 0.214
Middle East (Oman) 247.5 ± 3.4 × 10−4 10 15 11 36 598.80 160.20 0.111 0.243
Overall 148.1 ± N/C × 10−4 10 39 11 40 583.61 157.39 0.263 0.245
a Data from Brazil from a previous study [13] added for comparison
Dn, Ds: Number of fixed non-synonymous and synonymous differences between species (S. mansoni and S. rodhaini)
Pn, Ps: Number of polymorphic non-synonymous and synonymous differences within species (S. mansoni)
N: Number of non-synonymous sites
S: Number of synonymous sites
pN/pS = (Pn/N)/(Ps/S)
Ka/Ks = (Dn/N)/(Ds/S)
N/C: not computable
https://doi.org/10.1371/journal.ppat.1007881.t002
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SmSULT-OR (Fig 2). These mutations will generate truncated proteins that do not contain the
active site. Other mutations, such as p.L179P, p.P225S or p.W120R, were either close enough
to the OXA or the 3’-phosphoadenosine-5’-phosphosulfate (PAPS) binding sites or showed
potential steric hindrance or structural deformation likely to have an effect on protein activity.
Other mutations, such as p.A74T, p.P106S or p.Q176R, were on the surface of the protein, dis-
tant to any active site, and therefore unlikely to have an impact.
Functional assay of OXA binding. We used an in vitro OXA activation assay to function-
ally assay the impact of mutations on SmSULT-OR activity for four newly discovered muta-
tions and the two known OXA-R mutations (Fig 3). The known resistant mutations, p.C35R
Fig 2. Mapping of the resistance mutations on the gene sequence and structure of Schistosoma mansoni SmSULT-OR sulfotransferase. Exon 1 and exon 2 are
represented in orange and beige, respectively. Single nucleotide polymorphisms and duplication/deletion events are represented in cyan and magenta, respectively. (A)
Linear representation of the SmSULT-OR gene showing the relative position of the mutations and their translation in amino acid sequences. (B) Positions of mutations on
the SmSULT-OR protein. Oxamniquine is represented in yellow, 3’-phosphoadenosine-5’-phosphosulfate (PAPS) co-factor is represented in green.
https://doi.org/10.1371/journal.ppat.1007881.g002
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and p.E142del, showed from zero to very low level of OXA activation, as expected [10]. p.
L179P showed a similarly low level of activation. The mutations p.S160L and p.P225S showed
intermediate OXA activation: we conservatively classed these as OXA sensitive alleles. p.P106S
Fig 3. Enzymatic activity of recombinant Schistosoma mansoni SmSULT-OR sulfotransferase expressed from
different allelic variants. This in vitro oxamniquine activation assay quantifies DNA-oxamniquine complexes by
scintillation (counts per minute). (A) Bars show the mean of three replicates, while error bars are S.E.M. (B) The
triangular matrix shows the p-values from the pairwise comparisons (Tukey’s HSD). The color is proportional to the
level of significance, from white (not significant) to red (most significant). Enzyme carrying known loss-of-function
mutations, such as p.C35R or p.E142del, as well as a newly identified variant (p.L179P) showed no or low oxamniquine
activation, while two newly identified variants (p.S160L and p.P225S) showed intermediate activation. The newly
identified p.P106S did not impair oxamniquine activation.
https://doi.org/10.1371/journal.ppat.1007881.g003
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showed similar activity to the wild type and p.S160L. We were able to produce recombinant
protein p.W120R but all our attempts to fold this protein were unsuccessful. This mutation
clearly has a dramatic impact on protein stability as predicted by visual inspection and thermo-
dynamic modelling results (below). We considered this mutation to be OXA-R.
Thermodynamic modelling. We used thermodynamic modelling to evaluate the poten-
tial impact of substitutions on protein stability (indels such as p.E142del cannot be modelled).
The difference in free enthalpy (ΔΔG) ranged from -2.942 to 19.826 for the 37 mutations (Fig
4). Among those, p.L179P and p.C35R which have the greatest impact on OXA activation (Fig
3) showed the second and third highest ΔΔG, respectively. p.W120R, for which we were unable
to fold recombinant protein, showed the highest ΔΔG, consistent with a dramatic impact on
stability. p.S160L and p.P225S showed intermediate ΔΔG consistent with the results of the
OXA activation assay.
In total, we identified 6 independent OXA-R mutations in Old World parasite populations
examined using these three approaches (Table 3, Fig 2). These included 1 duplication, 1
known indel, 2 new indels and 3 SNPs.
Frequency of OXA-R alleles
Having determined which of the mutations identified are likely to cause OXA-R, we measured
the frequency of resistance variants and the frequency of resistant parasites in each population
(Table 3, Fig 5). To accurately identify resistance alleles and parasites, we phased our variant
calling data on the first 3 Mb of the chromosome 6 (corresponding to 30,812 variable sites).
West African samples carried only two resistance variants (p.S12X and p.E142del). East African
samples carried five resistance variants, two of them at a frequency over 0.05 (p.W120R and p.
N171IfsX28). The p.W120R mutation was also found at high frequency in Middle East (0.065).
We found the highest frequency of OXA-R alleles in East Africa (14.91%, 17/114), followed by
the Middle East (6.25%, 14/224), West Africa (4.29%, 3/70), and Brazil (1.85%, 7/378).
Most parasites carried OXA-R alleles in the heterozygous state and are predicted to be OXA
sensitive. Heterozygous OXA-sensitive parasites were found in West and East Africa (8.6%
and 19.3%, respectively), Middle East (12.5%) and in Brazil (1.6%). Parasites that are homozy-
gous for OXA-R alleles at SmSULT-OR (but not necessarily carrying the same resistance vari-
ant) are OXA-R. We found homozygous parasites predicted to be phenotypically OXA-R at a
frequency of 5.26% (3/57) in East Africa and 1.06% (2/189) in South America only (Fig 5).
Haplotype analysis of SmSULT-OR and flanking regions
We used our phased data to investigate the haplotypes surrounding our resistance variant (p.
E142del) in the Old and New World (Caribbean) (Table 1) and to investigate whether these
resistance alleles derived from a common ancestor. This is of interest because it would suggest
that these alleles predate the slave trade. We identified an identical 102.5 kb haplotype block
around p.E142del shared between the Caribbean sample and one of the West African samples
from Niger (Fig 6A). This haplotype block contained 399 SNPs that varied in at least one of the
205 parasites examined (all samples except those from Brazil where haplotype data were not
available). We used a minimum spanning network to investigate haplotype relationships using
the 399 bi-allelic variants found in this 102.5 kb block across all phased haplotypes (Fig 6B).
The haplotypes associated with the p.E142del OXA-R alleles found in both Puerto Rico and
Niger clustered together, consistent with a common origin for West African and Caribbean p.
E142del OXA-R mutations.
The p.E142del mutation was also identified in Brazil [13] but we sequenced the SmSUL-
T-OR exons only, rather than complete exomes, for these Brazilian samples preventing
Standing variation for oxamniquine resistance in schistosomes
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reconstruction of extended haplotypes. This Brazilian p.E142del was also found associated
with two mutations (p.P67L and g.4720C>T) found in West Africa but without the p.L256W
found in samples from the Caribbean and Niger. Similarly, the p.E142del was also found in a
Tanzanian sample but this sample had a distinct haplotype from those found in West Africa
(Fig 6). These results suggest either that there are several independent origins of East and West
African p.E142del mutations, or alternatively, that the p.E142del is extremely old and has dis-
tinctive flanking haplotypes resulting from recombination and mutation.
Discussion
Evidence for standing genetic variation for OXA resistance
Two lines of evidence support the view that standing variation is the source of OXA-R alleles
in schistosomes. First, we have indirect evidence: OXA-R alleles are geographically widespread
in Africa and the Middle East despite limited treatment with OXA (or hycanthone, its struc-
tural analog; [18]) in these regions. Furthermore, that OXA-R alleles are found at high fre-
quency in East Africa, where there has been minimal use of OXA, while OXA-R alleles are
found at low frequency in Brazil, where OXA has been used extensively, is also consistent with
the idea that mutation and drift, rather than selection, explain the patterns of variation
observed. The second line of evidence is more direct: we showed that an OXA-R mutation, p.
E142del, with an identical 102.5 kb flanking haplotype, is sampled from both West African
and Caribbean schistosomes. This result strongly suggests that p.E142del alleles were present
in West Africa prior to the transatlantic slave trade (1501–1867) [19], and were transferred to
Fig 4. In silico evaluation of mutations on protein stability. We computed the difference in free enthalpy (ΔΔG)
between the mutated and the wild type proteins. The higher the ΔΔG, the more unstable is the mutated protein. Only
single amino acid changes within the resolved crystal structure were examined. For completeness, we included
mutations from our current dataset and from previous studies [10,13]. Grey bars correspond to known sensitive alleles.
Red bars correspond to validated resistance alleles. Grey labels correspond to mutations identified previously from
South America [13].
https://doi.org/10.1371/journal.ppat.1007881.g004
Table 3. OXA-R mutations scored in the Schistosoma mansoni SmSULT-OR gene and their frequency in the New and Old World.
Nucleic acid mutation Amino acid mutation Mutation frequency
South America (Brazil)a
n = 189
West Africa
(Senegal / Niger)
n = 25 / n = 10
East Africa
(Tanzania)
n = 57
Middle East
(Oman)
n = 112
c.3dupGTTTATCCATAATG p.I2VfsX3 - - 0.0096 -
c.35C>A p.S12X - 0.014 - -
c.103T>C p.C35R 0.0027 - - -
c.358T>C p.W120R - - 0.0510 0.065
c.424_426delGAA p.E142del 0.008 0.035 0.0098 -
c.510delT p.N171IfsX28 - - 0.0625 -
c.536T>C p.L179P - - 0.0089 -
Total frequency 0.0107 0.044 0.1418 0.065
The code used for nucleic acid mutations indicates the sequence type (c = coding), the position, and the mutation type (X>Y = substitution of X by Y, insN = insertion
of N, delN = deletion of N, dupN = duplication of N). The code used for amino acid mutations indicates the sequence type (p = protein), the reference amino acid, the
position, and finally the alternative amino acid, and when frame shift (fs) occurs, the position of the stop codon (X) after the mutation. For details about the
nomenclature, see Ogino et al. [79].
a Data from Brazil were obtained in a previous study [13] added for comparison.
https://doi.org/10.1371/journal.ppat.1007881.t003
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the New World on ships carrying West African slaves. Hence, OXA-R alleles were segregating
within S. mansoni populations at least 470 years before deployment of OXA in the 1970s [20].
Our molecular data are backed up by clinical observations from the early use of OXA. Resis-
tant parasites were detected in Brazil in the 1970s [21,22], before any mass drug administration
[14]. Similar observations of S. mansoni infected patients resistant to OXA treatment were
made in East Africa [23]. The existence of OXA-R parasites was confirmed experimentally by
infecting mice with parasites isolated from patients that were parasite positive following drug
treatment [21–23]. Together these observations support the existence of segregating OXA-R
alleles in schistosome populations before OXA deployment for parasite control.
Differences in OXA treatment efficacy between East and West Africa
Given the variation in OXA-R frequencies that we observe in different geographical samples, it
is interesting to examine the literature on clinical treatment efficacy of OXA for treating schis-
tosomiasis patients. Early trials of OXA to treat patients with intestinal schistosomiasis resulted
in multiple treatment failures in Egypt, East Africa and South Africa [23–27]. As a conse-
quence, the WHO recommended use of higher doses of OXA in East Africa, compared with
West Africa [28]. Human host metabolism did not explain this lack of efficacy because the
OXA availability in blood was the same or higher in the East African patient populations than
in West African or South American populations [29,30]. Therefore, the presence of resistant
parasites was the most likely explanation. OXA-R parasites were identified in Kenya by treat-
ing mice infected with parasites from patients showing poor treatment response [23]. We
Fig 5. World map showing proportion of resistance and sensitive alleles in South America (Brazil), West Africa (Senegal and Niger), East Africa (Tanzania) and
Middle East (Oman). Number of homozygous (hmz) and heterozygous (htz) parasites for resistance alleles, and total number of parasites sampled (N) are shown below
the pie charts. East Africa showed the highest frequency of resistance alleles and resistant parasites. Data from Brazil from a previous study [13] was added for comparison.
https://doi.org/10.1371/journal.ppat.1007881.g005
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observed a 14.91% frequency of OXA-R alleles (and 5.26% frequency of homozygous OXA-R
parasites) in East Africa compared with 4.29% frequency of OXA-R alleles (and no homozy-
gous OXA-R parasites) in West Africa. Our results provide a molecular explanation for the
poor treatment response observed in East Africa, relative to other locations.
Fig 6. Common origin of the p.E142del mutation in the Old and New World. (A) Haplotype variation in all the samples bearing p.E142del from Caribbean (HR9),
Niger (NE) and Tanzania (TZ) across a 102.5 kb region of chr. 6. Each row represents a chromosome, HR9 was used as reference, blank squares reflect HR9 allele state,
and black squares correspond to the alternative allele. Relative bp position to p.E142del (0 bp) is shown on the x-axis. The first and last variants showed on the block
correspond to the break of the haplotype block. The Caribbean sample (HR9) and a Nigerien sample (Sm.NE_Di158.1) share an identical haplotype block of 102.5 kb. (B)
Minimum spanning network of 410 haplotypes of the 102.5 kb region previously identified. The network was built using 399 bi-allelic variants. Node size is proportional
to sample size (smallest node: n = 1; biggest node n = 50). Nodes with samples carrying p.E142del are circled in blue. Caribbean and West African haplotypes carrying p.
E142del clustered together indicating a common origin. The p.E142del from East Africa has different flanking haplotypes.
https://doi.org/10.1371/journal.ppat.1007881.g006
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Implications for development of OXA derivatives
OXA kills S. mansoni but not S. haematobium or S. japonicum. OXA derivatives are currently
under development to obtain more potent molecules acting against all three schistosome spe-
cies infecting humans. In fact, OXA derivatives that kill adult worms of the three species in
vitro have now been developed [31]. The low frequency of homozygous OXA-R parasites in S.
mansoni suggests that OXA derivatives will result in imperfect cure rate for this species, partic-
ularly in East Africa. However, the primary purpose of generating OXA derivatives is to treat
S. haematobium and S. japonicum, perhaps as a partner drug for praziquantel (PZQ). Examin-
ing natural variation in homologous sulfotransferase genes from these two species (ShSUL-
T-OR and SjSULT-OR) to better understand the potential for resistance evolution will be
critical if OXA derivatives are to be developed to control these parasites.
Implications of standing variation for drug resistance evolution
Standing variation in drug resistance genes has a major impact on how fast resistance evolves [2].
If resistance alleles are already present in the population prior to treatment, drug resistance has
the potential to spread much more rapidly because there is no waiting time for a resistance muta-
tion to appear de novo (Fig 7A) [3]. An increasing number of examples support this view. The
nematode Caenorhabditis elegans carries a large diversity of β-tubulin alleles allowing worms to
be resistant to benzimidazoles (BZ) [32]. In the filarial worm Onchocerca volvulus, standing varia-
tion appears to be involved in resistance to ivermectin [6]. Standing variation is also involved in
herbicide resistance in plants: resistance alleles from the weed Alopecurus myosuroides were iden-
tified in plant collection almost 100 years before herbicides were used [33]. Antibiotic resistance
provides particularly dramatic examples of standing variation: plasmids encoding multidrug
resistance were found in frozen bacteria isolated from the permafrost demonstrating that antibi-
otic resistance plasmids were already present thousands of years ago [34,35].
We do not want to give the impression that standing variation is the only source of varia-
tion for evolution of drug resitance. In the case of other well studied helminth parasites, such
as Haemonchus contortus and Teladorsagia circumcincta, resistance alleles are consistent with
evolution through recurrent de novo mutations or very rare standing variants. While selection
of rare pre-existing BZ resistance alleles was shown in French farms [36], selection of de novo
resistance mutations, associated with different haplotypes, was shown to be common in UK
farms [37].
The fact that there is strong evidence of standing variation in OXA resistance but not in BZ
resistance may reflect the differences in the nature of the mutation underlying resistance. In
the case of OXA, resistance is due to loss-of-function mutations resulting in non functional
SmSULT-OR. As a consequence, mutations can occur in any position that disrupts substrate
binding or protein structure. Hence mutations are expected to arise frequently and will exist in
natural populations. In contrast, mutations underlying BZ resistance occur in specific position
within the β-tubulin gene. As consequence, such mutations occur much more rarely. Further-
more because β-tubulin is an essential gene, mutations that disrupt protein structure and result
in non functional proteins are strongly selected against and cannot reach high frequency.
Standing variation for OXA resistance alleles could arise by drift, or alternatively as a result
of selective forces other than OXA treatment. For example, Hahnel et al. [32] demonsrated BZ
resistance in natural population of C. elegans which are not targetted by BZ drugs and specu-
lated that natural compound with similar structure to benzimidazoles could have pre-selected
for benzimidazole resistance alleles. In the case of our OXA-R mutations in SmSULT-OR, we
do not know what selective forces might be involved (see also discussion in section Prediction
of the resistance spread).
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Drug resistance in parasitic helminths infecting livestock or humans is now recognized as a
potential concern for control efforts, but was neglected for a long time using the argument that
the slow reproduction rate of worms would greatly delay resistance evolution [38]. The obser-
vation that resistance alleles exist as standing variation within multiple pathogen or parasite
populations in the absence of drug treatment suggests previous optimism about the shelf life of
drugs was poorly founded. If resistance alleles are already at relatively high frequency in popu-
lations when new drugs are deployed, resistance may evolve extremely rapidly [3,5].
Prediction of the resistance spread
We can use the frequency of resistance allele to model resistance spread in parasite popula-
tions. In the case of OXA resistance, using an Ne estimate of 65,000 [39], OXA-R alleles spread
from 15% starting frequency to fixation in 170 generations in 100% of simulations when selec-
tion is strong (s = 0.1). Assuming a generation time between 3 months and 1 year, this is equiv-
alent to a period of 42.5 to 170 years (Fig 7A). However, if OXA-R alleles were evolving de
novo, simulations indicate that fixation will occur rarely (0.04% of the simulations) and this
would take 1,197 generations (corresponding to a period of 299.25 to 1,197 years) from the
time a mutation arises. We can use the observed frequency of OXA-R alleles segregating in
East African populations to make predictions about the spread of phenotypically resistant par-
asites (i.e. those homozygous for OXA-R alleles) (Fig 7B). If we use a frequency of 10% resis-
tant parasites to denote unacceptable efficacy (this threshold is used for antimalarial drugs
[40]) then this threshold will be reached in 19 to 444 generations (4.75 to 444 years) using a
range of selection coefficients (from 0.01 to 0.2). The selection coefficients driving spread of
drug resistance alleles in schistosomes is not known, but the range we have used covers mea-
sured selection coefficients driving drug resistance spread in another human parasite (Plasmo-
dium falciparum) [41,42]. These simulations suggest that, while OXA-R allele frequencies are
relatively high in East Africa, OXA derivatives could still be extremely effective for schistosome
control in the short-medium term, particularly if deployed as a combination therapy, part-
nered with a second drug with a different mode of action (e.g. PZQ).
Our simple models for predicting spread of OXA-R alleles under drug selection ignore fit-
ness costs of OXA-R alleles, which might limit the rate of spread. The fitness cost of inactive
SmSULT-OR in the absence of drug treatment still needs to be assessed accurately [13] but the
occurrence of natural homozygotes for defective alleles suggests limited costs. The exact role of
this enzyme in schistosome biology is not known. Sulfotransferases transfer the sulfo group
from a donor (usually PAPS) to the substrate, resulting in inactivation or solubilization of the
substrate [43]. Substrates can be endogenous signal molecules (hormones, neurotransmitters)
or exogenous chemicals. In the latter case, sulfotransferases play a role in detoxifying natural
or synthetic toxins [43], but sometimes they do the opposite by activating pro-drugs as
observed with the anti-tumor drug N-benzyl indolecarbinols [44] or OXA [10,45]. Because the
same enzyme can sulfate both endogenous and exogenous compounds, it is often difficult to
Fig 7. Impact of starting allele frequency on OXA-R allele change. (A) Monte Carlo simulation over 1,500
generations using strong selection (selection coefficient (s) = 0.1) on a population size (N) of 65,000 with a starting
allele frequency (p(R)) of 0.15 for standing variation or 1/(2N) for new mutation. These simulations underestimate
time to fixation for true de novo mutation, because we do not account for the waiting time for resistance to appear
which is dependant on the rate of drug resistance mutations and Ne [3]. The starting frequency of 0.15 corresponds to
the frequencies of OXA-resistance alleles observed in Kenya. (B) Change in frequency of resistant parasites (i.e.
homozygotes for OXA-R alleles) from standing variation under a range of selection coefficients. The dashed lines
correspond to the two thresholds (10% and 20%) at which treatment efficacy would be compromised. The numbers at
the dashed lines correspond to the parasite generations needed to cross these thresholds. These predictions are
deterministic, because we expect minimal stochastic variation when starting resistance allele frequencies are high.
https://doi.org/10.1371/journal.ppat.1007881.g007
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determine their exact biological role. In schistosomes, we speculate that SmSULT-OR could
have roles in regulating endogenous molecules as well as detoxifying chemicals present in their
environment (i.e. in the feces, water, snail or human blood, etc.).
Molecular markers for resistance surveillance
Molecular markers of OXA-R now allow efficient monitoring of the distribution of OXA-R
alleles in schistosome populations. This approach is widely used for other parasites and patho-
gens such as malaria parasite [46] and HIV [47]. For schistosome, collections such as SCAN
which contain thousands of parasite samples from multiple locations [17] will be extremely
valuable for this work: regular sampling in different endemic regions will help to update the
resistance landscape. However, not all identified SmSULT-OR mutations will lead to resistance,
so it is critical that molecular screening is paired with functional evaluation or computational
prediction, as we have done here.
PZQ is the only drug currently available to treat schistosomiasis and effort in mass drug
administration has recently been expanded 10 fold [48], with a target of administering 250 mil-
lion treatments per year, increasing selective pressure for PZQ resistance. We suspect that
standing variation for PZQ resistance is also likely, because this trait is easy to select in the lab-
oratory. This has been done by several groups using independent laboratory populations, and
resistance has spread within very few generations [49–54], strongly suggesting that resistance
alleles were already present in these laboratory populations. Furthermore, the laboratory popu-
lations used for selection were isolated before PZQ was available [23,55] and so were not
exposed to drug selection. Molecular markers for monitoring the frequency of PZQ-R in natu-
ral parasite populations would be extremely valuable, as demonstrated by our work on
OXA-R.
Materials and methods
Ethics statement
African samples. Samples from Senegal and Niger were collected as part of the EU-CON-
TRAST project [56], a multidisciplinary alliance to optimize schistosomiasis control and trans-
mission surveillance in sub-Saharan Africa, as detailed in Webster et al. [57] with ethical
approval granted by ethical committees of the Ministry of Health (Dakar, Senegal), and the
Niger National Ethical Committee (Niamey, Niger) with additional ethical approval obtained
from the St Mary’s Hospital Local Ethics Research Committee, R&D office (part of the Impe-
rial College Research Ethics Committee (ICREC; EC no. 03.36. R&D no. 03/SB/033E)), in
combination with the ongoing CONTRAST and Schistosomiasis Control Initiative (SCI)
activities.
For the Tanzanian samples collected as part of the Schistosomiasis Consortium for Opera-
tional Research and Evaluation (SCORE), ethical approvals were granted by the Imperial Col-
lege Research Ethics Committee and the SCI Ethical approval (EC no. 03.36. R&D no. 03/SB/
033E); the National Institute for Medical Research (NIMR, reference no. NIMR/HQ/R.8a/Vol.
IX/1022); University of Georgia Institutional Review Boards, Athens, GA (2011-10353-1).
Following routine procedures in the field, the objectives of the study were first explained to
the local village chiefs and political and religious authorities who gave their consent to conduct
the study. Written consent for the schoolchildren to participate in longitudinal monitoring of
the national control programme for schistosomiasis was given by head teachers, and/or village
chiefs where there were no schools, due to the fact that in African villages, written consent
of the child’s guardian is often very difficult to obtain owing to the associated impoverished
conditions and often low literacy. Each individual child also gave verbal consent before
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recruitment. Following sampling, a praziquantel treatment (40 mg.kg−1) was offered to
infected participants.
Omani samples. We obtained ethical clearance from the Sultan Qaboos University and
the Ministry of Health of Oman to use positive stool samples for schistosomiasis collected by
the Ministry of Health of Oman during epidemiological screening. Ethical approval was given
by the Medical Research and Ethical Committee (MREC) of the Non-Communicable Disease
Control Section of the Directorate General of Health Affairs, Headquarters, Ministry of
Health, Oman (no. MH/DGHA/DSDC/NCD/R&S/167/01).
We obtained ethical approvals of animal studies in France from the French Ministère de
l’E´ducation Nationale, de la Recherche et de la Technologie, from the French Ministère de
l’Agriculture et de la Pêche (agreement no. A 66040), and from the French Direction De´parte-
mentale de la Protection des Populations (no. C 66-136-01 with prefectoral order no. 2012-
201-0008). Certificate for animal experimentation was given to H.M. (authorization no. C
66.11.01; articles no. R 214–87, R 214–122 and R 215–10). Housing, breeding and animal care
followed the guidelines of the French CNRS. The different protocols used in this study had
been approved by the French veterinary agency from the DRAAF Languedoc-Roussillon
(Direction Re´gionale de l’Alimentation, de l’Agriculture et de la Forêt), Montpellier, France
(authorization no. 007083).
Sampling
African samples. S. mansoni miracidia were collected from individual patients in two dif-
ferent West African countries in 2007: 27 patients from two locations in Senegal, and 17
patients from two locations in Niger (S3 Table) [57,58]. Additionally, S. mansoni miracidia
were collected as part of the SCORE program from 64 children in seven villages on the shores
of Lake Victoria in Tanzania (East Africa) in January 2012 (S3 Table) [59].
Collection of miracidia was performed as previously described [57,60]. Briefly, individual
stool samples from positive patients were homogenized through a mesh and washed through
with water. The content was then transferred in a Pitchford funnel assembly, washed with
additional water, and the filtered homogenate was drained into a Petri dish. The Petri dish
containing the homogenate was then left in bright ambient light (not direct sunlight) to allow
hatching of miracidia. Miracidia were visualized under a dissecting microscope and individu-
ally captured in 3–5 μL of water using a micropipette. Miracidia were then pipetted individu-
ally onto Whatman FTA cards for DNA preservation. Cards were allowed to dry for 1 hour
and then stored for future research [57,58,60].
Omani samples. The Omani schistosome samples were collected during 8 field trips,
from 2001 to 2015, in different areas in Dhofar, Oman and originated from either Homo sapi-
ens, Rattus rattus or Biomphalaria pfeifferi (S3 Table): 11 patients from 4 localities, 2 rats from
2 localities, 26 snails from 3 localities.
We obtained schistosome adult worms from naturally infected rats and from laboratory
infected mice. The mice were infected with cercariae from naturally infected snails or from
laboratory snails infected with miracidia isolated from stool samples. We collected miracidia
from stool samples as described in Mone´ et al. [61]. We exposed Biomphalaria pfeifferi snails
to miracidia as described in Mouahid et al. [62]. We maintained laboratory and naturally
infected snails at constant temperature (26˚C) and balanced photoperiod (12h light / 12h
dark) and fed them with fresh lettuce ad libitum. Prior to infection, we anaesthetized the mice
by intraperitoneal injection of an anesthetic solution (0.01 mL.g-1 of mouse body weight). We
prepared the anaesthetic solution using 0.5 mL of Rompun (20 mg.mL-1; Bayer) and 1 mL of
Imalgène (100 mg.mL-1; Rhoˆne Me´rieux) diluted in 8.5 mL of autoclaved NaCl 8.5 ‰.
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Abdomens of anesthetized mice were shaved and exposed during 1 hour to cercariae shed
from laboratory or naturally infected snails. Cercariae from naturally infected snails were kept
in 95˚ ethanol when the number of cercariae was too low for mouse infection. Laboratory
infected mice or naturally infected rats were euthanized by intraperitoneal injection of sodium
pentobarbital solution (1.1 mL diluted in 10 mL of ethanol 10%). We recovered adult worms
by perfusion [63]; the worms were washed in NaCl 8.5 ‰, and single worms (female or male)
were fixed in 95˚ ethanol and preserved at -20˚C. Worms and cercariae were washed in 1X TE
buffer for 1 hour prior to DNA extraction.
DNA processing and library preparation
We amplified DNA and sequenced exomes from single miracidia preserved on FTA cards (1
miracidium per patient) for African samples or from DNA extracted from worms or cercariae
for Omani samples. FTA-preserved samples were processed following our published protocol
[64]. Briefly we punched a 2 mm disc containing the miracidium from the FTA card, washed it
with the FTA Purification Reagent (GE Healthcare Life Sciences), rinsed it twice with TE−1
buffer, and finally dried it. DNA from single worms and cercariae were extracted using the
DNeasy Blood and Tissue kit (Qiagen) following the tissue protocol with an incubation time
of 2h at 56˚C and an elution in 200 μL. Samples were quantified using the Qubit dsDNA HS
assay kit (Invitrogen).
We then performed whole genome amplification (WGA) on each FTA punch or on 2 μL or
4 μL of DNA solution using the Illustra GenomiPhi V2 DNA Amplification kit (GE Healthcare
Life Sciences). Amplified DNA was purified with the SigmaSpinTM Sequencing reaction
Clean-up (Sigma-Aldrich), following the manufacturer protocol. We quantified purified sam-
ples using the Qubit dsDNA BR assay (Invitrogen). DNA samples that failed WGA were
cleaned up and concentrated using the Genomic DNA Clean & Concentrator kit (Zymo
Research) following the manufacturer protocol and these samples with concentrated DNA
were used to perform a new WGA.
Because WGA reactions are non-specific, we performed qPCR on each sample from FTA
cards to quantify proportion of schistosome DNA (i.e., check for an excess of amplified DNA
from the environment (water, fecal matter, etc.)). We excluded samples that showed less than
100 schistosome genomes copies in 20 ng of DNA which were not suitable for subsequent
exome capture. We assessed genome copies by quantifyng the S. mansoni α-tubulin single
copy gene [64].
We prepared exome capture libraries on the selected African samples and on all the success-
fully amplified Omani samples using the pre-capture pooling method of the SureSelect XT2
Target Enrichment System (Agilent) [64]. Finally, we sequenced libraries on a HiSeq 2500 and
data were demultiplexed using the Casava pipeline. Raw sequencing data are accessible from
the NCBI Sequence Read Archive under BioProject accession numbers PRJNA439266,
PRJNA560069, PRJNA560070.
Alignment, variant calling and phasing
We aligned sequences as described in Le Clec’h et al. [64]. Briefly, we aligned data against the
v5 S. mansoni genome using BWA and SAMtools, realigned around indels using GATK, PCR
duplicates were marked using picard and Q-score were recalibrated using GATK.
To identify variants in the SmSULT-OR (Smp_089320) gene, we performed a variant calling
using FreeBayes (v1.1.0-46-g8d2b3a0) [65] in the first 3 Mb of the chromosome 6. We used a
minimum base quality (-q) of 20 and a minimum mapping quality (-m) of 30. We included
mutation sites identified previously [10,13] in order to genotype these sites specifically for
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further comparison. We defined 4 populations: Caribbean (HR), West Africa (SN and NE),
East Africa (TZ) and Middle-East (OM). We excluded variants supported by less than 4 reads
using VCFtools (v0.1.14) [66]. We then used vcf-subset from VCFtools to remove sites with
reference allele only. We adjusted variant positions using vt normalize (v0.5772-60f436c3)
[67]. We finally used Beagle (v4.1) [68] to first estimate genotypes and to then phase data. This
approach resolves haplotypes using statistical models rather than by direct linkage of SNPs on
short reads. Unphased variant calling data and scripts used to analyze the data are available on
Zenodo (DOI: 10.5281/zenodo.2850876 and 10.5281/zenodo.3370039, respectively).
Genetics analysis
We performed all the genetics analysis using phased exome data. We handled the VCF data in
R (R v3.5.0 [69]) using the vcfR package (v1.8.0.9) [70]. We determined the longest haplotype
block from the samples carrying the p.E142del using a custom R code after filtering invariable
sites in these samples. We built the haplotype network using the R package poppr (v2.8.1)
[71,72] after selecting variants within the longest haplotype coordinates showing no more than
20% of missing data. We computed the frequency of the OXA-R allele using a custom R script
and functional annotation obtained through a custom bash script.
We generated haplotype sequences of the coding sequence only for the Old World samples
using the updated phased VCF data exported from R and the BCFtools (v1.2) [73]. We gener-
ated haplotypes of the South American samples from previous genotyping using a custom
bash script. We included the SmSULT-OR homologue sequence from S. rodhaini previously
identified [13]. We aligned the haplotypes using Clustal Omega (v1.2.2) [74]. We determined
nucleotide diversity, number of synonymous and non-synonymous sites using DnaSP software
(v6.12.01) [75]. Populations were defined as described in the previous section. Scripts used to
analyze the data are available on Zenodo (DOI: 10.5281/zenodo.3370039).
Recombinant SmSULT-OR protein production and OXA activation assay
We produced recombinant SmSULT-OR proteins following Chevalier et al. [13]. Briefly, muta-
tions were introduced in the cloned SmSULT-OR gene sequence (Smp_089320; GenBank acces-
sion no. HE601629.1) and introduced into Escherichia coli for protein production. Proteins
were extracted from bacterial culture and purified on an affinity chromatography column. His-
tag was removed using Tobacco etch virus (TEV) protease, the solution was dialyzed overnight
and passed through affinity chromatography again to remove His-tag and TEV protease. The
sample was loaded onto a GE-pre-packed Q anion exchange column and eluted, and the pooled
fractions were dialyzed overnight. The protein was finally concentrated at 10 mg.mL-1.
We tested the impact of a subset of the mutations observed on OXA activation using an in
vitro assay [13]. We tested the ability of recombinant SmSULT-OR proteins to activate OXA
in a protease inhibitor cocktail with sheared S. mansoni gDNA as a final target for the tritiated
OXA pre-mixed with ATP, MgCl2 and PAPS co-factor. After 2.5 h of incubation at 37˚C, the
reaction was stopped and DNA was extracted three times. Radioactivity in the remaining aque-
ous phase containing the DNA and in water (blank) was counted in a liquid scintillation spec-
trometer. Blank values were subtracted from sample values. We performed three independent
reactions for each recombinant protein.
Evaluation of impact of mutations on protein stability
We first visually assessed the scored mutations on the SmSULT-OR protein structure (PDB
code 4MUB [10]) using the mutagenesis function of PyMol software (v2.3.0; Schro¨dinger,
LLC).
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We then used the Rosetta package (v3.9) to test the impact of scored mutations on protein
stability. We used the ddg_monomer application to compute the difference in free enthalpy
(ΔΔG) between the mutated (amino acid substitutions only) and the wild-type protein. The
higher the ΔΔG, the more unstable is the mutated protein. For this, we prepared ligand files
(OAQ and A3P) by downloading SDF files containing all ligand structures from SmSULT-OR
crystals available from the Protein Data Bank website. We modified SDF files to add hydrogens
using Openbabel (v2.4.0) [76], and generated params files using molfile_to_params.py from
Rosetta. We used the structure of SmSULT-OR to generate a constraint file using the minimi-
ze_with_cst application and the convert_to_cst_file.sh scripts. We removed ligand informa-
tion from the constraint file. For each mutation, we finally generated a resfile and ran the
ddg_monomer application with 50 iterations and options adapted from the protocol 16 of Kel-
logg et al. [77]. Scripts used to run this analysis are available on Zenodo (DOI: 10.5281/
zenodo.3370039).
Statistical analysis
We conducted statistical analyses using R (v3.5.0) [69]. We performed simulations using a
modified version of the driftR simulator [78]. The OXA activation assay data were tested for
normality using a Shapiro-Wilk and compared by a parametric ANOVA followed by a Tukey
post-hoc test.
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